Citi analyst, Joel Beatty, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) cutting his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE